Press releases
DexTech Medical’s Myeloma Study, Dose Group 2, DMC Gives OK for Dose Group 3
16 October, 2025The study is being conducted at Karolinska University Hospital Huddinge and at Uddevalla Hospital. The treatment lasts for a total of 14 weeks with 2 doses per month. Three dose […]
DexTech: Invitation to open Annual General Meeting and notice
3 October, 2025On Tuesday, November 4, 2025, DexTech Medical AB (“DexTech”) will hold its Annual General Meeting. Subject to availability, non-shareholders are also welcome to participate without voting rights. At the meeting, […]
DexTech Medical AB: Annual Report 2024-07-01 – 2025-06-30
19 September, 2025The Board of Directors and the CEO of Dextech Medical AB (DexTech), org.nr. 556664-6203, with its registered office in Stockholm, hereby submits the Annual Report for the financial year 2024-07-01 […]
Year-end report 1 July 2024 – 30 June 2025
29 August, 2025Summary of year-end report Fourth quarter (2025-04-01 – 2025-06-30) • Net sales amounted to SEK 0.0 million (0.0) • Operating profit amounted to SEK -1.6 million (-1.6) • Earnings per […]
DexTech Medical’s Myeloma Study, Dose Group 2
20 August, 2025The study is being conducted at Karolinska University Hospital Huddinge and at Uddevalla Hospital. The treatment lasts for a total of 14 weeks with 2 doses per month. Three dose […]
DexTech Medical’s patent application regarding GMP manufacturing of OsteoDex is approved
19 May, 2025OsteoDex is DexTech’s lead candidate for the treatment of castration-resistant prostate cancer and has completed clinical phase 2. In October 2023, the Company filed a patent application with the EPO […]
Interim report July 1, 2024 – March 31, 2025
29 April, 2025Summary of the third quarter (2025-01-01 – 2025-03-31) Net sales amounted to MSEK 0,0 (0,0) Operating profit/loss amounted to MSEK -1,3 (-1,5) Earnings per share* SEK -0.07 (-0.08) Summary of […]
DexTech Medical’s myeloma study, strong follow-up results
23 April, 2025The study is being conducted at Karolinska University Hospital Huddinge and Uddevalla Hospital. The treatment lasts for a total of 14 weeks with 2 doses per month. Three dose levels […]
Half-year report July 1 – December 31, 2024
27 February, 2025By “Company” or “DexTech” is meant DexTech Medical AB with organization number 556664-6203. Summary of the second quarter (2024-10-01 – 2024-12-31) Net sales amounted to MSEK 0,0 (0,0) Operating profit/loss […]
DexTech Medical is funded through Q4, 2026
25 February, 2025Regarding the ongoing Phase 1 study investigating the efficacy of OsteoDex in patients with progressive treatment-resistant multiple myeloma (MM). Progressive disease means that the disease progresses and does not respond […]